PhaseBio Announces Receipt of Minutes of End-of-Phase 1 Meeting with the FDA and Alignment on a Single, Non-Randomized Phase 3 Trial to Support BLA Submission for PB2452
Stock Information for PhaseBio Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.